Literature DB >> 11929814

Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes.

Jia-Long Fang1, Frederick A Beland, Daniel R Doerge, Doris Wiener, Chantal Guillemette, M Matilde Marques, Philip Lazarus.   

Abstract

UDP-glucuronosyltransferase (UGT)-mediated glucuronidation of benzo(a)pyrene-trans-7,8-dihydrodiol (BPD), precursor to the potent mutagen benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide, may be an important pathway in the detoxification of benzo(a)pyrene. To better characterize this pathway in humans, high-pressure liquid chromatography (HPLC) was used to detect glucuronide conjugates of BPD formed in vitro. Three peaks were detected by HPLC after incubation of racemic BPD with human liver microsomes; these were identified as monoglucuronides by liquid chromatography-mass spectrometry analysis. Proton nuclear magnetic resonance spectroscopy of isolated fractions, combined with HPLC analysis of the glucuronide products from human liver microsomal incubations with purified benzo(a)pyrene-trans-7S,8S-dihydrodiol [(+)-BPD] and benzo(a)pyrene-trans-7R,8R-dihydrodiol [(-)-BPD] forms of BPD, indicated that peak 1 contained the 7-glucuronide of 7S,8S-BPD (BPD-7S-Gluc), peak 2 was a mixture of the 7-glucuronide of 7R,8R-BPD (BPD-7R-Gluc) and the 8-glucuronide of 7S,8S-BPD (BPD-8S-Gluc), and peak 3 contained the 8-glucuronide of 7R, 8R-BPD (BPD-8R-Gluc). In liver microsomes, peak 1 (BPD-7S-Gluc) was the largest peak observed, whereas in microsomes from aerodigestive tract tissues, peak 2 (both BPD-7R-Gluc and BPD-8S-Gluc) was the largest HPLC peak observed. The liver enzymes UGT1A1 and UGT2B7 formed BPD-7S-Gluc as the major diastereomer, whereas UGT1A8 and UGT1A10, extrahepatic enzymes present in the aerodigestive tract, preferentially formed both BPD-7R-Gluc and BPD-8S-Gluc. In addition, both UGT1A9 and UGT1A7 preferentially formed BPD-7R-Gluc. No detectable glucuronidating activity against BPD was observed by UGT1A3, UGT1A4, UGT1A6, UGT2B4, UGT2B15, or UGT2B17. The affinity of individual UGT enzymes as determined by K(m) analysis was UGT1A10 > UGT1A9 > UGT1A1 > UGT1A7 for (-)-BPD and UGT1A10 > UGT1A9 > UGT2B7 approximately UGT1A1 > UGT1A7 for (+)-BPD. These results suggest that several UGTs may play an important role in the overall glucuronidation of BPD in humans, with UGT1A1, UGT1A7, UGT1A9, UGT1A10 and potentially UGT1A8 playing an important role in the glucuronidation of the procarcinogenic (-)-BPD enantiomer, and that the stereospecific activity exhibited by different UGTs against BPD is consistent with tissue-specific patterns of BPD glucuronide diastereomer formation and UGT expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929814

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

2.  Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.

Authors:  Baojian Wu; Xiaoqiang Wang; Shuxing Zhang; Ming Hu
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

3.  UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans.

Authors:  Hugo Girard; Lesley M Butler; Lyne Villeneuve; Robert C Millikan; Rashmi Sinha; Robert S Sandler; Chantal Guillemette
Journal:  Mutat Res       Date:  2008-07-16       Impact factor: 2.433

4.  Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer.

Authors:  Dongfang Tang; Yu C Zhao; Hongliang Liu; Sheng Luo; Jeffrey M Clarke; Carolyn Glass; Li Su; Sipeng Shen; David C Christiani; Wen Gao; Qingyi Wei
Journal:  Int J Cancer       Date:  2020-03-09       Impact factor: 7.396

5.  Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.

Authors:  Ebrahim Eskandari-Nasab; Mohammad Hashemi; Hamzeh Rezaei; Aliakbar Fazaeli; Mohammad Ali Mashhadi; Simin Sargholzaei Moghaddam; Farshid Arbabi; Mahdi Jahantigh; Mohsen Taheri
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

6.  UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.

Authors:  Nathan R Jones; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2014-01-23       Impact factor: 3.922

7.  Discovery of a widespread metabolic pathway within and among phenolic xenobiotics.

Authors:  Pahriya Ashrap; Guomao Zheng; Yi Wan; Tong Li; Wenxin Hu; Wenjuan Li; Hong Zhang; Zhaobin Zhang; Jianying Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-23       Impact factor: 11.205

8.  Importance of UDP-glucuronosyltransferase 1A1 expression in skin and its induction by UVB in neonatal hyperbilirubinemia.

Authors:  Kyohei Sumida; Makiko Kawana; Emi Kouno; Tomoo Itoh; Shuhei Takano; Tomoya Narawa; Robert H Tukey; Ryoichi Fujiwara
Journal:  Mol Pharmacol       Date:  2013-08-15       Impact factor: 4.436

9.  UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility.

Authors:  Rene M Balliet; Gang Chen; Ryan W Dellinger; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2009-12-09       Impact factor: 3.922

10.  Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.

Authors:  Y K Pithavala; M Tortorici; M Toh; M Garrett; B Hee; U Kuruganti; G Ni; K J Klamerus
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-15       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.